AYTU - Aytu BioScience, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.40
+0.40 (+13.33%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.00
Open2.97
Bid0.00 x 1200
Ask0.00 x 1000
Day's Range2.87 - 4.80
52 Week Range2.49 - 136.40
Volume1,628,852
Avg. Volume78,215
Market Cap6.125M
Beta4.56
PE Ratio (TTM)N/A
EPS (TTM)-5.68
Earnings DateFeb 7, 2018 - Feb 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • ACCESSWIRE4 days ago

    Aytu BioScience Announces Publication of Manuscript Summarizing Results from the Ongoing Natesto(R) Spermatogenesis Study

    ENGLEWOOD, CO / ACCESSWIRE / September 17, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the publication of a clinical trial update in the journal European Urology Focus on the effects of Natesto® on reproductive hormones and semen parameters. This study is being conducted at the University of Miami's Department of Urology, and Dr. Ranjith Ramasamy, MD, the Director of Reproductive Urology, is the study's principal investigator. The publication entitled, "Natesto Effects on Reproductive Hormones and Semen Parameters: Results from an Ongoing Single-center, Investigator-initiated Phase IV Clinical Trial" provides updated data on five of the 23 currently enrolled subjects, through six months of Natesto treatment.

  • ACCESSWIRE14 days ago

    Natesto(R) Q4 Revenue Increases 178% Sequentially; Q4 Product Revenue Increases 52% Sequentially

    Highest Ever Quarterly Net Revenue for Natesto Testosterone Nasal Gel ENGLEWOOD, CO / ACCESSWIRE / September 6, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on ...

  • ACCESSWIRE22 days ago

    Aytu BioScience to Report Fiscal Fourth Quarter 2018 Results and Business Update

    Live Conference Call and Webcast Scheduled for September 6, 2018, at 4:30 p.m. ET ENGLEWOOD, CO / ACCESSWIRE / August 30, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company ...

  • ACCESSWIRElast month

    Aytu BioScience Announces Accelerated Launch of ZolpiMist(TM) in the U.S.

    ENGLEWOOD, CO / ACCESSWIRE / August 13, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the accelerated launch of ZolpiMist™, an oral spray formulation of zolpidem tartrate (brand name Ambien®) and the only FDA-approved oral spray prescription sleep aid. The Aytu BioScience sales force begins promoting ZolpiMist to U.S. clinicians today in the domestic $1.8 billion non-benzodiazepine prescription sleep aid market.

  • ACCESSWIRElast month

    Aytu BioScience Announces Effectiveness of 1-for-20 Reverse Stock Split

    ENGLEWOOD, CO / ACCESSWIRE / August 10, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the company will effect a 1-for-20 reverse split of its issued and outstanding shares of common stock. The reverse stock split will become effective August 10, 2018 at 4:30 p.m. EDT. Shares of the company's common stock will trade on a split-adjusted basis beginning Monday, August 13, 2018.

  • ACCESSWIRE2 months ago

    Stock Performance Review on AVEO Pharma and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on AVEO sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • ACCESSWIRE2 months ago

    Aytu BioScience Announces Enrollment of First Twenty Patients in the Natesto(R) Spermatogenesis Study

    ENGLEWOOD, CO / ACCESSWIRE / July 17, 2018 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the first twenty patients have been enrolled in the company's investigator-initiated study assessing the impact of Natesto® on sperm production and gonadotropin levels. This study is being conducted at the University of Miami's Department of Urology, and Dr. Ranjith Ramasamy, MD, the Director of Reproductive Urology, is the study's principal investigator.

  • The Wall Street Journal2 months ago

    [$$] This Form of Ambien Now Costs Over 800% More

    A small Colorado drugmaker recently raised the price for a spray form of sleep aid Ambien by as much as 843%, the latest example of how some firms are increasing prices despite mounting pressure. The median price increase is 8%, but some specific increases have been far greater. Aytu BioScience Inc. raised the list price of a 7.7 milliliter bottle of its sleep aid Zolpimist to $659 from $69.88, while increasing the price of a 4.5 milliliter bottle by 747% to $329.50, according to RELX PLC’s Elsevier Gold Standard Drug Database.

  • ACCESSWIRE2 months ago

    Aytu BioScience Announces 7 Presentations of Clinical Findings for its Proprietary MiOXSYS(R) System at the 34th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE)

    - Multi-Center, Global Study Demonstrates that MiOXSYS Provides an Accurate Measure of Seminal Oxidative Stress that can be Standardized Globally Within Clinical Andrology and IVF Laboratories - Presentations ...

  • ACCESSWIRE3 months ago

    Free Pre-Market Technical Pulse on AVEO Pharma and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on AVEO sign up now at www.wallstequities.com/registration. Last Friday, shares in Cambridge, Massachusetts-based AVEO Pharmaceuticals Inc. ended the session 4.35% higher at $2.40.

  • ACCESSWIRE3 months ago

    Aytu BioScience Enters $1.8 Billion U.S. Prescription Sleep Aid Market with Exclusive License to Zolpimist(TM) to Expand Company's Commercial-Stage Product Portfolio

    ENGLEWOOD, CO / ACCESSWIRE / June 13, 2018 / Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the Company has exclusively licensed Zolpimist™ (zolpidem tartrate oral spray) in the United States and Canada. Annual sales in the U.S. prescription sleep aid category were $1.8 billion over the 12-month period ending February 2018, approximately the same as the testosterone replacement prescription category.1 The Company believes that the addition of Zolpimist will complement ongoing Natesto selling efforts among primary care physicians and add another revenue-generating product to the Company's portfolio.

  • Why You Need To Look At This Factor Before Buying Aytu BioScience Inc (NASDAQ:AYTU)
    Simply Wall St.4 months ago

    Why You Need To Look At This Factor Before Buying Aytu BioScience Inc (NASDAQ:AYTU)

    For Aytu BioScience Inc’s (NASDAQ:AYTU) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. AYTU is exposedRead More...

  • ACCESSWIRE4 months ago

    Wired News – Acceleron Pharma Commences PULSAR Phase-2 Trial of Sotatercept in Pulmonary Arterial Hypertension

    LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want access to our free research report on Acceleron Pharma Inc. (NASDAQ: XLRN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=XLRN as the Company's latest news hit the wire. On May 22, 2018, the Company announced that it has commenced the PULSAR Phase-2 trial of sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH), which is a chronic and life-changing disease that can lead to heart failure. Active-Investors.com is currently working on the research report for Aytu BioScience, Inc. (NASDAQ: AYTU), which also belongs to the Healthcare sector as the Company Acceleron Pharma.

  • ACCESSWIRE4 months ago

    Aytu BioScience, Inc. to Present at the 8th Annual LD Micro Invitational Investor Conference

    ENGLEWOOD, CO / ACCESSWIRE / May 23, 2018 / Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, announced today that it will be presenting at the 8th Annual LD Micro Invitational investor conference on Tuesday, June 5th, at 9:00 AM PST / 11:00 AM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health. The company currently markets two prescription products in the U.S.: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or ''Low T'') and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate-specific membrane antigen (PSMA) for prostate cancer detection and staging.

  • Benzinga4 months ago

    Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 14) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. (NYSE: ...

  • ACCESSWIRE4 months ago

    Aytu BioScience Provides Fiscal Third Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET

    ENGLEWOOD, CO / ACCESSWIRE / May 14, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today ...

  • ACCESSWIRE4 months ago

    Aytu BioScience CEO Issues Letter to Shareholders

    ENGLEWOOD, CO / ACCESSWIRE / May 8, 2018 / Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, has highlighted its progress of the company's commercial strategy in the below letter to shareholders. In response to multiple inquiries from interested stakeholders, I'm pleased to provide a short, high-level summary of the Company's progress as we continue launching Natesto in the U.S. while building our commercial capabilities and product portfolio. Since the Company's most recent communication we have made significant progress in both our execution in the field as well as with our patient reimbursement access through the introduction of the Natesto Support Program.

  • ACCESSWIRE5 months ago

    Aytu BioScience to Report Fiscal Third Quarter 2018 Results and Business Update

    ENGLEWOOD, CO / ACCESSWIRE / May 7, 2018 / Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the company will present its operational results for the fiscal third quarter 2018 on Monday, May 14, 2018, at 4:30 p.m. ET. The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Corporate Presentations & Media, at aytubio.com, for 90 days. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health.

  • ACCESSWIRE5 months ago

    Aytu BioScience Featured in Local ABC News Segment (VIDEO): "UM Doctors Test New Medication for Treating Men with Low Testosterone; Nasal Testosterone Gel doesn't Appear to have Negative Side Effects, Doctors Say."

    ENGLEWOOD, CO / ACCESSWIRE / May 3, 2018 / Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the field of urology, has been featured in a local ABC News segment presented by medical specialist anchor Kristi Krueger: "UM doctors test new medication for treating men with low testosterone. 'Doctors say there are two major side effects [to testosterone replacement therapy]. "One, it blocks the sperm production, especially for young men or men who wish to conceive in the future and are still interested in fertility and family building," said Dr. Ranjith Ramasamy, director of reproductive urology at the University of Miami Health System.' 'Ramasamy said testosterone therapy also blocks any natural testosterone production.

  • ACCESSWIRE6 months ago

    Aytu BioScience to Present at The MicroCap Conference on April 10th in New York City at the Essex House

    ENGLEWOOD, CO / ACCESSWIRE / April 3, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU) (the "Company") will be presenting at this year's MicroCap Conference on Tuesday, April 10, 2018 at 10:30 am. ...

  • ACCESSWIRE6 months ago

    Aytu BioScience Announces Exercise of Underwriters' Over-Allotment Option

    ENGLEWOOD, CO / ACCESSWIRE / March 28, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in ...

  • ACCESSWIRE6 months ago

    Aytu BioScience Presents New Research Findings for Natesto(R) at the Endocrine Society's 100th Annual Meeting

    Post-hoc Data Analysis Demonstrates Natesto's Restoration of Normal Testosterone Levels in Hypogonadal Men While Maintaining Normal Levels of Estradiol (E2) and Dihydrotestosterone (DHT), Which Are Frequently ...

  • Has Aytu BioScience Inc (NASDAQ:AYTU) Improved Earnings Growth In Recent Times?
    Simply Wall St.6 months ago

    Has Aytu BioScience Inc (NASDAQ:AYTU) Improved Earnings Growth In Recent Times?

    Today I will take a look at Aytu BioScience Inc’s (NASDAQ:AYTU) most recent earnings update (31 December 2017) and compare these latest figures against its performance over the past fewRead More...

  • Aytu BioScience Receives Market Registration for the MiOXSYS® System for Male Infertility in Mexico
    PR Newswire7 months ago

    Aytu BioScience Receives Market Registration for the MiOXSYS® System for Male Infertility in Mexico

    ENGLEWOOD, Colo., March 7, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that it has received registration in Mexico for the MiOXSYS System, from the Secretary of Health at Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS).  The MiOXSYS System will be distributed exclusively through IMP Medica, a distributor of medical products to urologists, andrologists, and fertility centers throughout Mexico and in key markets in Latin America. Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "Regulatory licenses and registrations are critical to our efforts of effectively penetrating these new markets.

  • Aytu BioScience Announces Closing of $12,000,000 Public Offering
    PR Newswire7 months ago

    Aytu BioScience Announces Closing of $12,000,000 Public Offering

    ENGLEWOOD, Colo., March 6, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the closing of its previously announced underwritten public offering for total gross proceeds of $12,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) Class A Units consisting of an aggregate of 19,520,000 shares of our Common Stock and Warrants to purchase an aggregate of 19,520,000 shares of Common Stock, at a public offering price of $0.45 per Class A Unit, and (ii) Class B Units consisting of 3,216 shares of our Series B Convertible Preferred Stock, with a stated value of $1,000, and convertible into an aggregate of 7,146,667 shares of Common Stock, and Warrants to purchase an aggregate of 7,146,667 shares of Common Stock, at a public offering price of $1,000 per Class B Unit.